Is parkinson's disease truly a prion-like disorder? An appraisal of current evidence

Neurology Research International

Volumn 2015, Issue , 2015, Pages

  Chauhan, Aneesha ^a   Jeans, Alexander F ^b  

^a HERTFORD COLLEGE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; NANOTUBE; PRION PROTEIN; ROTENONE; TUNNELING NANOTUBE; UNCLASSIFIED DRUG;

CELL THERAPY; CYTOTOXICITY; DISEASE COURSE; DOPAMINERGIC NERVE CELL; EXOSOME; HUMAN; IMMUNOFLUORESCENCE; LEWY BODY; MEMBRANE VESICLE; NONHUMAN; PARKINSON DISEASE; PRION DISEASE; PRIORITY JOURNAL; PROTEIN FOLDING; REVIEW;

EID: 84947648631     PISSN: 20901852     EISSN: 20901860     Source Type: Journal    
DOI: 10.1155/2015/345285     Document Type: Review

References (59)

1. L. M. de Lau and M. M. Breteler, "Epidemiology of Parkinsons disease, " The Lancet Neurology, vol. 5, no. 6, pp. 525-535, 2006.
2. D. F. Boland and M. Stacy, "The economic and quality of life burden associated with Parkinsons disease: a focus on symptoms, "The American Journal of Managed Care, vol. 18, no. 7, pp. S168-S175, 2012.
3. S. B. Dunnett, A. Bjrklund, and O. Lindvall, "Cell therapy in Parkinsons disease-stop or go?" Nature Reviews Neuroscience, vol. 2, no. 5, pp. 365-369, 2001.
4. J. H. Kordower, Y. Chu, R. A. Hauser, T. B. Freeman, and C. W. Olanow, "Lewy body-like pathology in long-termembryonic nigral transplants in Parkinsons disease, " Nature Medicine, vol. 14, no. 5, pp. 504-506, 2008.
5. J. H. Kordower, Y. Chu, R. A. Hauser, C. W. Olanow, and T. B. Freeman, "Transplanted dopaminergic neurons develop PDpathologic changes: a second case report, " Movement Disorders, vol. 23, no. 16, pp. 2303-2306, 2008.
6. J.-Y. Li, E. Englund, J. L. Holton et al., "Lewy bodies in grafted neurons in subjects with Parkinsons disease suggest host-tograft disease propagation, " Nature Medicine, vol. 14, no. 5, pp. 501-503, 2008.
7. N. P. Visanji, P. L. Brooks, L. N. Hazrati, and A. E. Lang, "The prion hypothesis in Parkinsons disease: braak to the future, " Acta Neuropathologica Communications, vol. 1, p. 2, 2013.
8. M. C. Rodriguez-Oroz, M. Jahanshahi, P. Krack et al., "Initial clinical manifestations of Parkinsons disease: features and pathophysiological mechanisms, " The Lancet Neurology, vol. 8, no. 12, pp. 1128-1139, 2009.
9. J. H. Kordower, C. W. Olanow, H. B. Dodiya et al., "Diseaseduration and the integrity of the nigrostriatal system in Parkinsons disease, " Brain, vol. 136, no. 8, pp. 2419-2431, 2013.
10. M. G. Spillantini, M. L. Schmidt, V. M. Y. Lee, J. Q. Trojanowski, R. Jakes, and M. Goedert, "α-synuclein in Lewy bodies, " Nature, vol. 388, no. 6645, pp. 839-840, 1997.
11. A. B. Singleton, M. Farrer, J. Johnson et al., "α-Synuclein locus triplication causes Parkinsons disease, " Science, vol. 302, no. 5646, p. 841, 2003.
12. H. Fujiwara, M. Hasegawa, N. Dohmae et al., "α-synuclein is phosphorylated in synucleinopathy lesions, " Nature Cell Biology, vol. 4, no. 2, pp. 160-164, 2002.
13. M. Hasegawa, H. Fujiwara, T. Nonaka et al., "Phosphorylated α-synuclein is ubiquitinated in α-synucleinopathy lesions, " Journal of Biological Chemistry, vol. 277, no. 50, pp. 49071-49076, 2002.
14. D. M. Sampathu, B. I. Giasson, A. C. Pawlyk, J. Q. Trojanowski, and V. M.-Y. Lee, "Ubiquitination of α-synuclein is not required for formation of pathological inclusions in α-synucleinopathies, " The American Journal of Pathology, vol. 163, no. 1, pp. 91-100, 2003.
15. D. Ebrahimi-Fakhari, I. Cantuti-Castelvetri, Z. Fan et al., "Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of α-synuclein, " Journal of Neuroscience, vol. 31, no. 41, pp. 14508-14520, 2011.
16. S. B. Prusiner, "Novel proteinaceous infectious particles cause scrapie, " Science, vol. 216, no. 4542, pp. 136-144, 1982.
17. S. B. Prusiner, "Molecular biology of prion diseases, " Science, vol. 252, no. 5012, pp. 1515-1522, 1991.
18. J. Collinge, "Prion diseases of humans and animals: their causes and molecular basis, " Annual Review of Neuroscience, vol. 24, pp. 519-550, 2001.
19. W. C. Guest, J. M. Silverman, E. Pokrishevsky, M. A. ONeill, L. I. Grad, and N. R. Cashman, "Generalization of the prion hypothesis to other neurodegenerative diseases: an imperfect fit, " Journal of Toxicology and Environmental Health Part A, vol. 74, no. 22-24, pp. 1433-1459, 2011.
20. D. J. Irwin, J. Y. Abrams, L. B. Schonberger et al., "Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone, " JAMA Neurology, vol. 70, no. 4, pp. 462-468, 2013.
21. O. Rascol, P. Payoux, F. Ory, J. J. Ferreira, C. Brefel-Courbon, and J. L. Montastruc, "Limitations of current Parkinsons disease therapy, " Annals of Neurology, vol. 53, supplement 3, pp. S3-S12, 2003.
22. C. R. Freed, P. E. Greene, R. E. Breeze et al., "Transplantation of embryonic dopamine neurons for severe Parkinsons disease, " The New England Journal of Medicine, vol. 344, no. 10, pp. 710-719, 2001.
23. C. W. Olanow, C. G. Goetz, J. H. Kordower et al., "A doubleblind controlled trial of bilateral fetal nigral transplantation in Parkinsons disease, " Annals of Neurology, vol. 54, no. 3, pp. 403-414, 2003.
24. I. Mendez, A. iuela, A. Astradsson et al., "Dopamine neurons implanted into people with Parkinsons disease survive without pathology for 14 years, " Nature Medicine, vol. 14, no. 5, pp. 507-509, 2008.
25. A. Aguzzi and A. M. Calella, "Prions: protein aggregation and infectious diseases, " Physiological Reviews, vol. 89, no. 4, pp. 1105-1152, 2009.
26. L. A. Volpicelli-Daley, K. C. Luk, T. P. Patel et al., "Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death, " Neuron, vol. 72, no. 1, pp. 57-71, 2011.
27. M. Masuda-Suzukake, T. Nonaka, M. Hosokawa et al., "Pathological alpha-synuclein propagates through neural networks, " Acta Neuropathologica Communications, vol. 2, no. 1, p. 88, 2014.
28. C. J. R. Dunning, S. George, and P. Brundin, "Whats to like about the prion-like hypothesis for the spreading of aggregated α-synuclein in Parkinson disease?" Prion, vol. 7, no. 1, pp. 92-97, 2013.
29. K. C. Luk, C. Song, P. OBrien et al., "Exogenous α-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells, " Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 47, pp. 20051-20056, 2009.
30. C. Hansen, E. Angot, A.-L. Bergstrm et al., "α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells, " Journal of Clinical Investigation, vol. 121, no. 2, pp. 715-725, 2011.
31. S. Aulic, T. T. N. Le, F. Moda et al., "Defined alpha-synuclein prion-like molecular assemblies spreading in cell culture, " BMC Neuroscience, vol. 15, article 69, 2014.
32. R. Borghi, R. Marchese, A. Negro et al., "Full length α-synuclein is present in cerebrospinal fluid from Parkinsons disease and normal subjects, " Neuroscience Letters, vol. 287, no. 1, pp. 65-67, 2000.
33. H.-J. Lee, S. Patel, and S.-J. Lee, "Intravesicular localization and exocytosis of α-synuclein and its aggregates, " Journal of Neuroscience, vol. 25, no. 25, pp. 6016-6024, 2005.
34. K. M. Danzer, L. R. Kranich, W. P. Ruf et al., "Exosomal cellto-cell transmission of alpha synuclein oligomers, " Molecular Neurodegeneration, vol. 7, no. 1, article 42, 2012.
35. P. Desplats, H.-J. Lee, E.-J. Bae et al., "Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein, " Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 31, pp. 13010-13015, 2009.
36. H.-J. Lee, J.-E. Suk, E.-J. Bae, J.-H. Lee, S. R. Paik, and S.-J. Lee, "Assembly-dependent endocytosis and clearance of extracellular α-synuclein, " The International Journal of Biochemistry and Cell Biology, vol. 40, no. 9, pp. 1835-1849, 2008.
37. J. H. Kordower, H. B. Dodiya, A. M. Kordower et al., "Transfer of host-derived alpha synuclein to grafted dopaminergic neurons in rat, " Neurobiology of Disease, vol. 43, no. 3, pp. 552-557, 2011.
38. K. Gousset, E. Schiff, C. Langevin et al., "Prions hijack tunnelling nanotubes for intercellular spread, " Nature Cell Biology, vol. 11, no. 3, pp. 328-336, 2009.
39. L. F. Agnati, D. Guidolin, F. Baluka et al., "A new hypothesis of pathogenesis based on the divorce between mitochondria and their host cells: possible relevance for alzheimers disease, " Current Alzheimer Research, vol. 7, no. 4, pp. 307-322, 2010.
40. H. Braak, K. del Tredici, U. Rb, R. A. I. de Vos, E. N. H. Jansen Steur, and E. Braak, "Staging of brain pathology related to sporadic Parkinsons disease, " Neurobiology of Aging, vol. 24, no. 2, pp. 197-211, 2003.
41. J. Lotharius and P. Brundin, "Pathogenesis of Parkinsons disease: dopamine, vesicles and alpha-synuclein, " Nature Reviews. Neuroscience, vol. 3, no. 12, pp. 932-942, 2002.
42. M. S. Planchard, S. E. Exley, S. E. Morgan, and V. Rangachari, "Dopamine-induced alpha-synuclein oligomers show self-and cross-propagation properties, " Protein Science, vol. 23, pp. 1369-1379, 2014.
43. F. Pan-Montojo, O. Anichtchik, Y. Dening et al., "Progression of Parkinsons disease pathology is reproduced by intragastric administration of rotenone in mice, " PLoS ONE, vol. 5, no. 1, Article ID e8762, 2010.
44. F. Pan-Montojo, M. Schwarz, C. Winkler et al., "Environmental toxins trigger PD-like progression via increased alphasynuclein release from enteric neurons in mice, " Scientific Reports, vol. 2, article 898, 2012.
45. T. Gasser, J. Hardy, and Y. Mizuno, "Milestones in PD genetics, " Movement Disorders, vol. 26, no. 6, pp. 1042-1048, 2011.
46. A. Lerner and A. Bagic, "Olfactory pathogenesis of idiopathic parkinson disease revisited, " Movement Disorders, vol. 23, no. 8, pp. 1076-1084, 2008.
47. L. Parkkinen, S. S. OSullivan, C. Collins et al., "Disentangling the relationship between lewy bodies and nigral neuronal loss in Parkinsons disease, " Journal of Parkinsons Disease, vol. 1, no. 3, pp. 277-286, 2011.
48. M. M. Tompkins and W. D. Hill, "Contribution of somal Lewy bodies to neuronal death, " Brain Research, vol. 775, no. 1-2, pp. 24-29, 1997.
49. L. V. Kalia, S. K. Kalia, P. J. McLean, A. M. Lozano, and A. E. Lang, "α-synuclein oligomers and clinical implications for parkinson disease, " Annals of Neurology, vol. 73, no. 2, pp. 155-169, 2013.
50. S. Simoneau, H. Rezaei, N. Sales et al., "In vitro and in vivo neurotoxicity of prion protein oligomers, " PLoS Pathogens, vol. 3, no. 8, article e125, 2007.
51. T. F. Outeiro, P. Putcha, J. E. Tetzlaff et al., "Formation of toxic oligomeric α-synuclein species in living cells, " PLoS ONE, vol. 3, no. 4, Article ID e1867, 2008.
52. K. C. Luk, V. Kehm, J. Carroll et al., "Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice, " Science, vol. 338, no. 6109, pp. 949-953, 2012.
53. E. Angot, J. A. Steiner, C. M. Tom et al., "Alpha-synuclein cellto-cell transfer and seeding in grafted dopaminergic neurons in vivo, " PLoS ONE, vol. 7, no. 6, Article ID e39465, 2012.
54. S. A. Peterson, T. Klabunde, H. A. Lashuel, H. Purkey, J. C. Sacchettini, and J. W. Kelly, "Inhibiting transthyretin conformational changes that lead toamyloidfibril formation, " Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 22, pp. 12956-12960, 1998.
55. T. Bartels, J. G. Choi, and D. J. Selkoe, "α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation, " Nature, vol. 477, no. 7362, pp. 107-111, 2011.
56. T. M. Fountaine and R. Wade-Martins, "RNA interferencemediated knockdown of α-synuclein protects human dopaminergic neuroblastoma cells from MPP+ toxicity and reduces dopamine transport, " Journal of Neuroscience Research, vol. 85, no. 2, pp. 351-363, 2007.
57. G. H. Petit, T. T. Olsson, and P. Brundin, "Review: the future of cell therapies and brain repair: parkinsons disease leads the way, " Neuropathology and Applied Neurobiology, vol. 40, no. 1, pp. 60-70, 2014.
58. E. M. Hartfield, M. Yamasaki-Mann, H. J. Ribeiro Fernandes et al., "Physiological characterisation of human iPS-derived dopaminergic neurons, " PLoS ONE, vol. 9, no. 2, Article ID e87388, 2014.
59. K. Vekrellis and L. Stefanis, "Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinsons disease and other synucleinopathies, " Expert Opinion onTherapeutic Targets, vol. 16, no. 4, pp. 421-432, 2012.